<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848390</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-1022</org_study_id>
    <nct_id>NCT03848390</nct_id>
  </id_info>
  <brief_title>Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).</brief_title>
  <official_title>Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the effects of modified time-restricted feeding and
      conventional dietary approaches in motivated obese fatty liver patients on biochemical
      markers, imaging studies, and anthropometric measurements.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alanine Amino Transferase (ALT) levels</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI) Z-score</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic steatosis on Magnetic Resonance Elastography of the Liver</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis on Magnetic Resonance Elastography of the Liver</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRIGLYCERIDE</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TOTAL CHOLESTEROL</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Baseline; 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum insulin</measure>
    <time_frame>Baseline; 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum glucose</measure>
    <time_frame>Baseline; 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Modified Time-restricted Feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional diet</intervention_name>
    <description>The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.</description>
    <arm_group_label>Conventional diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Modified Time-restricted Feeding</intervention_name>
    <description>The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.</description>
    <arm_group_label>Modified Time-restricted Feeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>At least 30 minutes of physical activity per day 5 times per week.</description>
    <arm_group_label>Conventional diet</arm_group_label>
    <arm_group_label>Modified Time-restricted Feeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Restricted consumption of sweetened beverages</intervention_name>
    <description>Restricted consumption of juice, soda, and other sweetened beverages.</description>
    <arm_group_label>Conventional diet</arm_group_label>
    <arm_group_label>Modified Time-restricted Feeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Motivated obese fatty liver patients aged 8 -18yrs with ALT &gt;80

        Exclusion Criteria:

          -  Patients with metabolic disorders,

          -  On certain medications (i.e., amiodarone, corticosteroids, methotrexate, select
             antipsychotics /antidepressants, HAART, valproic acid),

          -  Kwashiorkor

          -  Alcohol abuse,

          -  Rapid surgical weight loss,

          -  History of parenteral nutrition and

          -  Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Essam M Imseis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Sciences Center in Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Essam M Imseis, MD</last_name>
    <phone>713-500-5663</phone>
    <email>essam.imseis@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Essam M Imseis, MD</last_name>
      <phone>713-500-5663</phone>
      <email>essam.imseis@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Essam M. Imseis</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

